胶质母细胞瘤缩小治疗体积与放射性坏死及淋巴细胞减少率降低相关:一项汇总分析
该回顾性研究纳入257例接受手术及辅助放疗的成人胶质母细胞瘤患者,比较按MD安德森癌症中心(MDACC)或放射治疗肿瘤协作组(RTOG)指南治疗的结果。RTOG组计划靶体积更大(303.2 cm³ vs 430.7 cm³,P < .001)、无进展生存更差(6个月 vs 9个月,P = .031),放射性坏死率(34% vs 21%,P = .024)和严重淋巴细胞减少率(15% vs 7%,P = .044)更高;总生存无差异。多因素分析中治疗类型与无进展生存无关。
要点
- RTOG组较MDACC组计划靶体积更大(303.2 cm³ vs 430.7 cm³,P < .001)。
- RTOG组放射性坏死率34% vs MDACC组21%(P = .024),严重淋巴细胞减少率15% vs 7%(P = .044)。
- RTOG组无进展生存6个月 vs MDACC组9个月(P = .031),总生存无差异。
核心结论
- 按MDACC指南治疗的患者治疗体积更小、无进展生存改善、放射性坏死和严重淋巴细胞减少率更低。
- 校正预后因素后,多因素分析中治疗类型与无进展生存无关。
- 需要前瞻性研究来确认这些结局差异。
研究设计与样本
- 回顾性研究,纳入257例接受手术和辅助放疗的成人胶质母细胞瘤患者,中位诊断年龄60.1岁。
- 162例按MDACC指南治疗,95例按RTOG指南治疗。
- 主要结局为局部控制、无进展生存、总生存和放疗相关毒性,采用Kaplan-Meier法和Cox回归模型分析。
主要发现
- RTOG组中位计划靶体积430.7 cm³ vs MDACC组303.2 cm³(P < .001),两组大体肿瘤体积相似。
- RTOG组无进展生存6个月 vs MDACC组9个月(P = .031)。
- 两组总生存无差异。
- RTOG组放射性坏死率34% vs MDACC组21%(P = .024)。
- RTOG组严重淋巴细胞减少率15% vs MDACC组7%(P = .044)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文结论指出需要前瞻性研究来确认这些结局差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: There is marked variability in treatment fields for glioblastoma. We performed a retrospective study comparing outcomes of patients treated according to MD Anderson Cancer Center (MDACC) or Radiation Therapy Oncology Group (RTOG) guidelines and identified differences in treatment-related toxicity. METHODS AND MATERIALS: Adult patients with glioblastoma treated with surgery and adjuvant radiation treatment were included in this study. Primary outcomes were local control, progression-free survival (PFS), overall survival (OS), and radiation-related toxicity. PFS and OS were estimated using the Kaplan-Meier estimator. Univariate and multivariate analyses were conducted using Cox regression models. RESULTS: In total, 257 patients met the inclusion criteria with a median age of 60.1 years at diagnosis. There were 162 and 95 patients treated according to the MDACC or RTOG guidelines, respectively. Despite having similar gross tumor volumes, the RTOG cohort had a larger median planning target volume (303.2 cm³ vs 430.7 cm³, P < .001) and worse PFS (6 months vs 9 months, P = .031). There was no difference in OS between treatment techniques. Patients treated according to RTOG guidelines experienced higher rates of radionecrosis (34% vs 21%, P = .024) and severe lymphopenia (15% vs 7%, P = .044). CONCLUSIONS: Patients treated according to MDACC guidelines had smaller treatment volumes, improved PFS, and lower rates of radionecrosis and severe lymphopenia. However, when adjusting for prognostic factors, treatment type was not associated with PFS in multivariate analysis. Prospective investigation is warranted to confirm these differences in outcomes.
引用
- Matsui JK, Swanson D, Allen P, et al. Reduced Treatment Volumes for Glioblastoma Associated With Lower Rates of Radionecrosis and Lymphopenia: A Pooled Analysis. Adv Radiat Oncol. 2025. PMID: 40028224. doi:10.1016/j.adro.2025.101717
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。